Read our latest updates & insights

AbbVie outlines defence strategy for Humira® (adalimumab) competition in the US market. CEO Gonzalez stated that AbbVie’s strategy will be based on the strategy already employed in Europe and other markets, while also admitting that global competition was much more ag...

On 18 Feb 2020, BioPharma Reporter reported that AbbVie had outlined its defence strategy for Humira (adalimumab) competition in the US market. According to the BioPharma Reporter, AbbVIe CEO Gonzalez that explained AbbVie’s commercial US strategy will mimic the strat...

Despite receiving CHMP approval earlier this month, Pfizer has announced it does not currently plan to launch Amsparity® (adalimumab) in the EU, citing unfavourable market conditions. 

On 12 Feb 2020, Wockhardt announced divestment of assets to Dr Reddy’s, under which 62 products and a manufacturing facility will be sold for $259 million. Wockhardt stated that the funds will enable it to invest in biosimilars for the US market.

On 11 February 2020, Amgen sued Hospira in the District Court of Delaware, alleging Hospira’s aBLA for a proposed pegfilgrastim biosimilar infringes Amgen’s Neulasta patent for protein purification (no. 8,273,707).

Amgen sues Hospira in the District Court of Delaware, alleging Hospira’s aBLA for a proposed pegfilgrastim biosimilar infringes Amgen’s Neulasta patent for protein purification (no. 8,273,707).​

Significant biosimilar activities this fortnight include
05 Feb 20 | Merck announced a new spin-off company which will incorporate products from its Women’s Health, Legacy Brands and Biosimilars businesses. The company is yet to be named but will be independent ...

MSD announced a new spin-off company which will incorporate products from its Women’s Health, Legacy Brands and Biosimilars businesses. The company is yet to be named but will be independent and publicly traded with the transaction expected to be completed in Q1/2 202...

The US FDA and FTC announced joint efforts to facilitate update of biosimilars, and deter anti-competitive behaviour in the biopharma industry.

The FDA released draft guidance on promotional labelling and advertising for biosimilars, inviting comments from industry until 2 April 2020.